PROCEDURE FOR THE QUALITATIVE AND/OR QUANTITATIVE PROOF OF CELLS

Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells

PROCEDURE AND KIT FOR THE DIAGNOSTICS OR TREATMENT CONTROL OF COLON CANCER

Kit for diagnosis and monitoring of testicular tumors, comprises pairs of primers for amplifying specific markers in blood, allows early detection of metastasis

Kit for diagnosis, and monitoring treatment, of testicular tumors comprising a pair of oligonucleotide primers, each suitable for PCR (polymerase chain reaction) amplification of one of the complementary strands of a DNA test sequence (I) that encodes one of four marker proteins, is new. Kit for diagnosis, and monitoring treatment, of testicular tumors comprising a pair of oligonucleotide primers, each suitable for PCR (polymerase chain reaction) amplification of one of the complementary strands of a DNA test sequence (I) that encodes one of four marker proteins, i.e. alpha -fetoprotein (AFP); the beta -subunit of human chorionic gonadotropin (bHCG); placenta-specific and/or germ cell-specific alkaline phosphatase (PLAP/GCAP), is new. Independent claims are also included for the following: (1) microarray for diagnosis, and monitoring treatment, of testicular tumors comprising an arrangement of separate cells each carrying an oligonucleotide that can bind with part of the cDNA encoding the specified markers; and (2) diagnosis, and monitoring treatment, of testicular tumors in humans in which a blood sample is screened for presence of mRNA for the specified markers to identify tumor cells in the blood as an indication of possible metastasis.

Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells

This invention relates to a method for selecting and/or for qualitative and/or quantitative detection of predetermined biological cells from or in a sample containing biological cells, the sample being mixed with a predetermined combination of at least two antibodies and/or antibody derivatives, which bind preferentially with their binding sites to different epitopes of the cells to be selected or detected, and/or with at least one biospecific antibody and/or antibody derivative, which binds preferentially with its two binding sites to different epitopes of the cells to be selected or detected, which are separated from the sample with cells marked with at least one of the antibodies and/or antibody derivatives, and the separated cells being tested with a predetermined combination of at least two molecular-biological detection reagents, the at least two detection reagents reacting preferentially with at least one component of the cells to be selected or detected.

Selection and determination of specific cells, useful particularly for diagnosis and monitoring of tumors, by antibody-mediated selection then detecting specific mRNA

Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample, is new. Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample comprises treating the sample with: (i) a predetermined combination of at least two antibodies (Ab) and/or Ab derivatives which bind preferentially to different epitopes on (A); and/or (ii) at least one bispecific antibody (2Ab) and/or derivative which binds preferentially to different epitopes on (A). Cells labeled with at least one antibody are separated and tested with a predetermined combination of at least two molecular-biology detection reagents (R) that react with at least one component of (A). An Independent claim is also included for a diagnostic kit for the method comprising: (i) Ab and/or 2Ab; and (ii) (R).

OLIGONUCLEOTIDE ARRAY, NUCLEOTIDE DETECTION METHOD AND DEVICE THEREFOR

VERFAHREN ZUM QUALITATIVEN UND/ODER QUANTITATIVEN NACHWEIS VON ZELLEN

DIAGNOSIS KIT, DNA CHIP, AND METHODS FOR DIAGNOSING OR SUPERVISING THE TREATMENT OF TESTICULAR CANCER

VERFAHREN UND KIT ZUR DIAGNOSTIK ODER BEHANDLUNGSKONTROLLE VON DARMKREBS

Use of lithium dodecyl sulfate for stabilizing RNA in solution, particularly during purification of RNA from cell lysate

Use of lithium dodecyl sulfate (I) for stabilizing RNA in solution. An Independent claim is also included for a method of stabilizing RNA in a (biological) sample, samples containing animal and/or human cells, and/or in blood by adding a stabilizing reagent that contains (I).

Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür

Die vorliegende Erfindung bezieht sich auf eine Oligonukleotidanordnung mit einem Substrat, das mindestens ein Feld aufweist, wobei in dem zumindest einen Feld Oligonukleotide mit feldspezifischer Sequenz immobilisiert sind und wobei die immobilisierten Oligonukleotide des mindestens einen Feldes derart modifiziert sind, daß sie durch zumindest eine vorbestimmte oder alle Nukleasen, die spezifisch einzelsträngige Nukleinsäure spalten, nicht verdaubar sind. The present invention relates to an oligonucleotide arrangement with a substrate that has at least one field, wherein in the at least one field oligonucleotides with a field-specific sequence are immobilized and wherein the immobilized oligonucleotides of the at least one field are modified such that they are modified by at least one predetermined or all nucleases that specifically cleave single-stranded nucleic acid are not digestible.

Selection and determination of specific cells, useful particularly for diagnosis and monitoring of tumors, by antibody-mediated selection then detecting specific mRNA

Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample, is new. Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample comprises treating the sample with: (i) a predetermined combination of at least two antibodies (Ab) and/or Ab derivatives which bind preferentially to different epitopes on (A); and/or (ii) at least one bispecific antibody (2Ab) and/or derivative which binds preferentially to different epitopes on (A). Cells labeled with at least one antibody are separated and tested with a predetermined combination of at least two molecular-biology detection reagents (R) that react with at least one component of (A). An Independent claim is also included for a diagnostic kit for the method comprising: (i) Ab and/or 2Ab; and (ii) (R).

Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer

The invention relates to a diagnosis kit, a DNA chip, and to methods for diagnosing or supervising the treatment of testicular cancer, which are of greatest importance, in particular, within the scope of cancer prevention and post-treatment. The invention is essentially characterized in that the mRNA of testicular tumor markers is detected in a blood sample, whereby the tumor markers depict a tumor-associated gene expression. To this end, particularly beta-hCG, AFP, PLAP or GCAP come into question. The detection of the mRNA is carried out by reverse transcription in cDNA and by subsequently amplifying selected segments of the cDNA by means of polymerase chain reaction.

Method and kit for the diagnosis or treatment control of intestinal carcinoma

The invention relates to a diagnosis kit and to a method for the diagnosis or treatment control of intestinal carcinoma in a human being. According to the invention, the presence or absence of at least two different messenger-RNAs coding for several of the tumour marker proteins CK20, EGF-R, CEA, GA733.2, PDGF-β and/or stanniocalcin is detected in a human blood sample. The presence of intestinal tumour cells in the blood sample is then deduced therefrom, as is possible metastatic spread.

Verfahren zum qualitativen und/oder quantitativen nachweis von zellen

Verfahren und kit zur diagnostik oder behandlungskontrolle von brustkrebs

Die vorliegende Erfindung bezieht sich auf ein Verfahren und ein Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs bei einem Menschen. Dieses Verfahren basiert darauf, dass in einer Blutprobe des Menschen das Vorhandensein oder Fehlen von mindestens zwei verschiedenen mRNS erfasst wird, die für verschiedene der Tumormarkerproteine EGF-R, CEA, Stanniocalcin, CK20, MAGE-3, GA733.2, MUC1, Her-2/neu, Claudin-7 und/oder PDGF-β kodieren und daraus auf das Vorhandensein von Mammakarzinomzellen in der Blutprobe und damit auf mögliche Metastasierung geschlossen wird.